CRISPR-Ready ioMicroglia
Human iPSC-derived microglia expressing Cas9 for rapid gene knockout generation
CRISPR-Ready ioMicroglia are built from bit.bio's well-established wild type ioMicroglia Male, engineered to constitutively express Cas9 nuclease. Users can significantly cut the experimental timelines required to run functional genomics experiments in physiologically relevant cells, as they no longer needing to spend months engineering and characterising their own Cas9 stable iPSC lines or optimise differentiation protocols. With these cells, robust experimental readouts can be achieved by simply delivering gRNAs against your target gene. Users do not require prior expertise in iPSC differentiation or gRNA delivery optimisation.
These cells arrive ready for guide RNA (gRNA) delivery from day 1 to 18 post-thaw. Using our optimised lentivirus or lipid-based gRNA delivery protocol, users can maximise their knockout efficiency and start measuring readouts from gene knockouts and CRISPR screens within days. They arrive cryopreserved, ready for functional genomics, disease model generation, drug target identification and fundamental human biology research immediately after thaw. Additionally, they have been deterministically programmed from human iPSCs using opti-ox technology, meaning scalability and consistency are built-in. In days, they convert consistently to microglia characterised by >90% expression of P2RY12 and IBA1.